|Bid||21.61 x 900|
|Ask||21.62 x 800|
|Day's range||21.50 - 21.80|
|52-week range||16.63 - 32.23|
|Beta (5Y monthly)||1.73|
|PE ratio (TTM)||240.39|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||26 Jun 2007|
|1y target est||N/A|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...
Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.
As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.
FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.
Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.
Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.
Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
Mylan (MYL) delivered earnings and revenue surprises of 2.63% and -2.39%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Mylan, which posted higher-than-expected third-quarter profit with the help of cost constraints, said it would reassess products it sells outside United States and had nearly completed its review of U.S. products. The review process should not affect net profit, President Rajiv Malik said on a conference call with analysts. Mylan in July agreed to merge with Pfizer Inc's Upjohn unit that sells off-patent branded drugs.
Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.